Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD.
Journal
Nature reviews. Gastroenterology & hepatology
ISSN: 1759-5053
Titre abrégé: Nat Rev Gastroenterol Hepatol
Pays: England
ID NLM: 101500079
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
accepted:
13
06
2019
pubmed:
18
7
2019
medline:
4
12
2019
entrez:
18
7
2019
Statut:
ppublish
Résumé
Macrophages are the gatekeepers of intestinal immune homeostasis as they discriminate between innocuous antigens and potential pathogens to maintain oral tolerance. However, in individuals with a genetic and environmental predisposition, regulation of intestinal immunity is impaired, leading to chronic relapsing immune activation and pathologies of the gastrointestinal tract, such as IBD. As evidence suggests a causal link between defects in the resolution of intestinal inflammation and altered monocyte-macrophage differentiation in patients with IBD, macrophages have been considered as a novel potential target to develop new treatment approaches. This Review discusses the molecular and cellular mechanisms involved in the differentiation and function of intestinal macrophages in homeostasis and inflammation, and their role in resolving the inflammatory process. Understanding the molecular pathways involved in the specification of intestinal macrophages might lead to a new class of targets that promote remission in patients with IBD.
Identifiants
pubmed: 31312042
doi: 10.1038/s41575-019-0172-4
pii: 10.1038/s41575-019-0172-4
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
531-543Références
Schett, G. & Neurath, M. F. Resolution of chronic inflammatory disease: universal and tissue-specific concepts. Nat. Commun. 9, 3261 (2018).
pubmed: 30111884
pmcid: 6093916
Hunter, P. The inflammation theory of disease. The growing realization that chronic inflammation is crucial in many diseases opens new avenues for treatment. EMBO Rep. 13, 968–970 (2012).
pubmed: 23044824
pmcid: 3492709
Garrett, W. S., Gordon, J. I. & Glimcher, L. H. Homeostasis and inflammation in the intestine. Cell 140, 859–870 (2010).
pubmed: 20303876
pmcid: 2845719
Mowat, A. M. To respond or not to respond — a personal perspective of intestinal tolerance. Nat. Rev. Immunol. 18, 405–415 (2018).
pubmed: 29491358
Elliott, M. R., Koster, K. M. & Murphy, P. S. Efferocytosis signaling in the regulation of macrophage inflammatory responses. J. Immunol. 198, 1387–1394 (2017).
pubmed: 28167649
pmcid: 5301545
Bain, C. C. & Mowat, A. M. Macrophages in intestinal homeostasis and inflammation. Immunol. Rev. 260, 102–117 (2014).
pubmed: 24942685
pmcid: 4141699
de Souza, H. S. & Fiocchi, C. Immunopathogenesis of IBD: current state of the art. Nat. Rev. Gastroenterol. Hepatol. 13, 13–27 (2016).
pubmed: 26627550
van Furth, R. et al. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull. World Health Organ. 46, 845–852 (1972).
pubmed: 4538544
pmcid: 2480884
Jakubzick, C. et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 39, 599–610 (2013).
pubmed: 24012416
Hashimoto, D. et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38, 792–804 (2013).
Yona, S. et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 79–91 (2013).
doi: 10.1016/j.immuni.2012.12.001
Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841–845 (2010).
pubmed: 20966214
pmcid: 20966214
Hoeffel, G. et al. C-Myb
pubmed: 25902481
pmcid: 4545768
Ginhoux, F. & Guilliams, M. Tissue-resident macrophage ontogeny and homeostasis. Immunity 44, 439–449 (2016).
pubmed: 26982352
Shaw, T. N. et al. Tissue-resident macrophages in the intestine are long lived and defined by Tim-4 and CD4 expression. J. Exp. Med. 215, 1507–1518 (2018).
pubmed: 29789388
pmcid: 5987925
De Schepper, S. et al. Self-maintaining gut macrophages are essential for intestinal homeostasis. Cell 175, 400–415 (2018).
pubmed: 30173915
Bujko, A. et al. Transcriptional and functional profiling defines human small intestinal macrophage subsets. J. Exp. Med. 215, 441–458 (2018).
pubmed: 29273642
pmcid: 5789404
Guilliams, M. & Scott, C. L. Does niche competition determine the origin of tissue-resident macrophages? Nat. Rev. Immunol. 17, 451–460 (2017).
pubmed: 28461703
Bain, C. C. et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat. Immunol. 15, 929–937 (2014).
pubmed: 25151491
pmcid: 4169290
Bain, C. C. et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 6, 498–510 (2013).
pubmed: 22990622
Dai, X. M., Zong, X. H., Sylvestre, V. & Stanley, E. R. Incomplete restoration of colony-stimulating factor 1 (CSF-1) function in CSF-1-deficient Csf1op/Csf1op mice by transgenic expression of cell surface CSF-1. Blood 103, 1114–1123 (2004).
pubmed: 14525772
Ryan, G. R. et al. Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse (Csf1(op)/Csf1(op)) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis. Blood 98, 74–84 (2001).
pubmed: 11418465
Muller, P. A. et al. Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell 158, 300–313 (2014).
pubmed: 25036630
pmcid: 4149228
MacDonald, K. P. et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116, 3955–3963 (2010).
pubmed: 20682855
Arnold, I. C. et al. CD11c
pubmed: 26242598
Jung, S. et al. Analysis of fractalkine receptor CX
pubmed: 10805752
pmcid: 85780
Sehgal, A. et al. The role of CSF1R-dependent macrophages in control of the intestinal stem-cell niche. Nat. Commun. 9, 1272 (2018).
pubmed: 29593242
pmcid: 5871851
Schridde, A. et al. Tissue-specific differentiation of colonic macrophages requires TGFbeta receptor-mediated signaling. Mucosal Immunol. 10, 1387–1399 (2017).
pubmed: 28145440
pmcid: 5417360
Rugtveit, J. et al. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 112, 1493–1505 (1997).
pubmed: 9136827
Smythies, L. E. et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115, 66–75 (2005).
pubmed: 15630445
pmcid: 539188
Smythies, L. E. et al. Inflammation anergy in human intestinal macrophages is due to Smad-induced IkappaBalpha expression and NF-kappaB inactivation. J. Biol. Chem. 285, 19593–19604 (2010).
pubmed: 20388715
pmcid: 2885238
Ueda, Y. et al. Commensal microbiota induce LPS hyporesponsiveness in colonic macrophages via the production of IL-10. Int. Immunol. 22, 953–962 (2010).
pubmed: 21051439
Franchi, L. et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 13, 449–456 (2012).
pubmed: 22484733
pmcid: 3361590
Maheshwari, A. et al. TGF-beta2 suppresses macrophage cytokine production and mucosal inflammatory responses in the developing intestine. Gastroenterology 140, 242–253 (2011).
pubmed: 20875417
Schwarz, T. et al. T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine. PLOS Pathog. 9, e1003476 (2013).
pubmed: 23825956
pmcid: 3694851
Zigmond, E. et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity 40, 720–733 (2014).
pubmed: 24792913
Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K. & Muller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263–274 (1993).
pubmed: 8402911
Shouval, D. S. et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity 40, 706–719 (2014).
pubmed: 24792912
pmcid: 4513358
Girard-Madoux, M. J. et al. IL-10 control of CD11c
pubmed: 27027442
pmcid: 5077993
Glocker, E. O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033–2045 (2009).
pubmed: 19890111
pmcid: 2787406
Schenk, M., Bouchon, A., Birrer, S., Colonna, M. & Mueller, C. Macrophages expressing triggering receptor expressed on myeloid cells-1 are underrepresented in the human intestine. J. Immunol. 174, 517–524 (2005).
pubmed: 15611278
Kobayashi, T. et al. IL-10 regulates Il12b expression via histone deacetylation: implications for intestinal macrophage homeostasis. J. Immunol. 189, 1792–1799 (2012).
pubmed: 22786766
pmcid: 3411910
Simon, J. M. et al. Alterations to chromatin in intestinal macrophages link IL-10 deficiency to inappropriate inflammatory responses. Eur. J. Immunol. 46, 1912–1925 (2016).
pubmed: 27159132
pmcid: 5486994
Hirotani, T. et al. The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. J. Immunol. 174, 3650–3657 (2005).
pubmed: 15749903
Ip, W. K. E., Hoshi, N., Shouval, D. S., Snapper, S. & Medzhitov, R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science 356, 513–519 (2017).
pubmed: 28473584
pmcid: 28473584
Hadis, U. et al. Intestinal tolerance requires gut homing and expansion of FoxP3
Mortha, A. et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 343, 1249288 (2014).
pubmed: 24625929
pmcid: 4291125
Medina-Contreras, O. et al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J. Clin. Invest. 121, 4787–4795 (2011).
pubmed: 22045567
pmcid: 3226003
Kim, K. W. et al. In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood 118, e156–167 (2011).
pubmed: 21951685
pmcid: 4507037
Rescigno, M. et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2, 361–367 (2001).
pubmed: 11276208
Arques, J. L. et al. Salmonella induces flagellin- and MyD88-dependent migration of bacteria-capturing dendritic cells into the gut lumen. Gastroenterology 137, 579–587 (2009).
pubmed: 19375423
Man, A. L. et al. CX3CR1
pubmed: 27895168
Leonardi, I. et al. CX3CR1
pubmed: 29326275
pmcid: 5805464
Chang, P. V., Hao, L., Offermanns, S. & Medzhitov, R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl Acad. Sci. USA 111, 2247–2252 (2014).
pubmed: 24390544
Scott, N. A. et al. Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci. Transl Med. 10, eaao4755 (2018).
pubmed: 30355800
pmcid: 6548564
Chng, S. H. et al. Ablating the aryl hydrocarbon receptor (AhR) in CD11c+ cells perturbs intestinal epithelium development and intestinal immunity. Sci. Rep. 6, 23820 (2016).
pubmed: 27068235
pmcid: 4828637
Ishikawa, H. et al. Effect of intestinal microbiota on the induction of regulatory CD25
pubmed: 18460018
pmcid: 2432106
Atarashi, K. et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337–341 (2011).
pubmed: 21205640
Singh, R. et al. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. Nat. Commun. 10, 89 (2019).
pubmed: 30626868
pmcid: 6327034
Kim, M. et al. Critical role for the microbiota in CX3CR1
pubmed: 29980437
pmcid: 6051886
Anitha, M., Vijay-Kumar, M., Sitaraman, S. V., Gewirtz, A. T. & Srinivasan, S. Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology 143, 1006–1016 (2012).
pubmed: 22732731
pmcid: 3458182
Gustafsson, B. E., Midtvedt, T. & Strandberg, K. Effects of microbial contamination on the cecum enlargement of germfree rats. Scand. J. Gastroenterol. 5, 309–314 (1970).
pubmed: 5429896
Avetisyan, M. et al. Muscularis macrophage development in the absence of an enteric nervous system. Proc. Natl Acad. Sci. USA 115, 4696–4701 (2018).
pubmed: 29666241
Ortega-Gomez, A., Perretti, M. & Soehnlein, O. Resolution of inflammation: an integrated view. EMBO Mol. Med. 5, 661–674 (2013).
pubmed: 23592557
pmcid: 3662311
Fullerton, J. N. & Gilroy, D. W. Resolution of inflammation: a new therapeutic frontier. Nat. Rev. Drug Discov. 15, 551–567 (2016).
pubmed: 27020098
Mantovani, A., Bonecchi, R. & Locati, M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat. Rev. Immunol. 6, 907–918 (2006).
pubmed: 17124512
Fox, S., Leitch, A. E., Duffin, R., Haslett, C. & Rossi, A. G. Neutrophil apoptosis: relevance to the innate immune response and inflammatory disease. J. Innate Immun. 2, 216–227 (2010).
pubmed: 20375550
pmcid: 2956014
Lauber, K. et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113, 717–730 (2003).
pubmed: 12809603
Gude, D. R. et al. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a “come-and-get-me” signal. FASEB J. 22, 2629–2638 (2008).
pubmed: 18362204
pmcid: 2493451
Truman, L. A. et al. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood 112, 5026–5036 (2008).
pubmed: 18799722
Elliott, M. R. et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282–286 (2009).
pubmed: 19741708
pmcid: 2851546
Gordon, S. & Pluddemann, A. Macrophage clearance of apoptotic cells: a critical assessment. Front. Immunol. 9, 127 (2018).
pubmed: 29441073
pmcid: 5797608
A-Gonzalez, N. et al. Phagocytosis imprints heterogeneity in tissue-resident macrophages. J. Exp. Med. 214, 1281–1296 (2017).
pubmed: 28432199
pmcid: 5413334
Casanova-Acebes, M. et al. Neutrophils instruct homeostatic and pathological states in naive tissues. J. Exp. Med. 215, 2778–2795 (2018).
pubmed: 30282719
pmcid: 6219739
Cummings, R. J. et al. Different tissue phagocytes sample apoptotic cells to direct distinct homeostasis programs. Nature 539, 565–569 (2016).
pubmed: 27828940
pmcid: 5807003
Maddox, J. F. et al. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J. Biol. Chem. 272, 6972–6978 (1997).
pubmed: 9054386
Chiang, N. et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58, 463–487 (2006).
pubmed: 16968948
Godson, C. et al. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164, 1663–1667 (2000).
pubmed: 10657608
Fiorucci, S. et al. A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc. Natl Acad. Sci. USA 101, 15736–15741 (2004).
pubmed: 15505205
Gewirtz, A. T. et al. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 168, 5260–5267 (2002).
pubmed: 11994483
Mangino, M. J., Brounts, L., Harms, B. & Heise, C. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat. 79, 84–92 (2006).
pubmed: 16516812
Sugimoto, M. A., Sousa, L. P., Pinho, V., Perretti, M. & Teixeira, M. M. Resolution of inflammation: what controls its onset? Front. Immunol. 7, 160 (2016).
pubmed: 27199985
pmcid: 4845539
Serhan, C. N., Chiang, N. & Dalli, J. The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin. Immunol. 27, 200–215 (2015).
pubmed: 25857211
pmcid: 4515371
Neurath, M. F. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 7, 6–19 (2014).
pubmed: 24084775
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K. & Serhan, C. N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612–619 (2001).
pubmed: 11429545
Vong, L., Ferraz, J. G., Panaccione, R., Beck, P. L. & Wallace, J. L. A pro-resolution mediator, prostaglandin D
pubmed: 20547854
Li, J. et al. Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation. EMBO Mol. Med. 9, 571–588 (2017).
pubmed: 28341703
pmcid: 5412792
Kong, D. et al. PKA regulatory IIalpha subunit is essential for PGD2-mediated resolution of inflammation. J. Exp. Med. 213, 2209–2226 (2016).
pubmed: 27621415
pmcid: 5030806
Bystrom, J. et al. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood 112, 4117–4127 (2008).
pubmed: 18779392
pmcid: 2581990
Shiraishi, H. et al. Prostaglandin E2 is a major soluble factor produced by stromal cells for preventing inflammatory cytokine production from dendritic cells. Int. Immunol. 20, 1219–1229 (2008).
pubmed: 18640970
Koga, K. et al. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 30, 372–383 (2009).
pubmed: 19285436
Brown, S. L. et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J. Clin. Invest. 117, 258–269 (2007).
pubmed: 17200722
pmcid: 1716207
Tessner, T. G., Muhale, F., Riehl, T. E., Anant, S. & Stenson, W. F. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J. Clin. Invest. 114, 1676–1685 (2004).
pubmed: 15578100
pmcid: 529281
Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M. & Gutkind, J. S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310, 1504–1510 (2005).
pubmed: 16293724
Chinen, T. et al. Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. Nat. Commun. 2, 190 (2011).
pubmed: 21304519
pmcid: 3105338
Bouma, G. & Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521–533 (2003).
pubmed: 12876555
Libioulle, C. et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLOS Genet. 3, e58 (2007).
pubmed: 17447842
pmcid: 1853118
Dalli, J. & Serhan, C. N. Pro-resolving mediators in regulating and conferring macrophage function. Front. Immunol. 8, 1400 (2017).
pubmed: 29163481
pmcid: 5671941
Buckley, C. D., Gilroy, D. W. & Serhan, C. N. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40, 315–327 (2014).
pubmed: 24656045
pmcid: 4004957
Gobbetti, T. et al. Protectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection. Proc. Natl Acad. Sci. USA 114, 3963–3968 (2017).
pubmed: 28356517
Bento, A. F., Claudino, R. F., Dutra, R. C., Marcon, R. & Calixto, J. B. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J. Immunol. 187, 1957–1969 (2011).
pubmed: 21724996
Marcon, R. et al. Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J. Immunol. 191, 4288–4298 (2013).
pubmed: 24038091
Belluzzi, A. et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N. Engl. J. Med. 334, 1557–1560 (1996).
pubmed: 8628335
Barbosa, D. S. et al. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition 19, 837–842 (2003).
pubmed: 14559317
Romano, C., Cucchiara, S., Barabino, A., Annese, V. & Sferlazzas, C. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn’s disease: a double-blind, randomized, placebo-controlled study. World J. Gastroenterol. 11, 7118–7121 (2005).
pubmed: 16437657
pmcid: 4725070
Pull, S. L., Doherty, J. M., Mills, J. C., Gordon, J. I. & Stappenbeck, T. S. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc. Natl Acad. Sci. USA 102, 99–104 (2005).
pubmed: 15615857
Seno, H. et al. Efficient colonic mucosal wound repair requires Trem2 signaling. Proc. Natl Acad. Sci. USA 106, 256–261 (2009).
pubmed: 19109436
Leoni, G. et al. Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J. Clin. Invest. 123, 443–454 (2013).
pubmed: 23241962
Quiros, M. et al. Macrophage-derived IL-10 mediates mucosal repair by epithelial WISP-1 signaling. J. Clin. Invest. 127, 3510–3520 (2017).
pubmed: 28783045
pmcid: 5669557
Saha, S. et al. Macrophage-derived extracellular vesicle-packaged WNTs rescue intestinal stem cells and enhance survival after radiation injury. Nat. Commun. 7, 13096 (2016).
pubmed: 27734833
pmcid: 5065628
Baillie, J. K. et al. Analysis of the human monocyte-derived macrophage transcriptome and response to lipopolysaccharide provides new insights into genetic aetiology of inflammatory bowel disease. PLOS Genet. 13, e1006641 (2017).
pubmed: 28263993
pmcid: 5358891
Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
pubmed: 3491803
pmcid: 3491803
Schwerd, T. et al. Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn’s disease. Gut 66, 1060–1073 (2017).
pubmed: 26953272
Smith, A. M. et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease. J. Exp. Med. 206, 1883–1897 (2009).
pubmed: 19652016
pmcid: 2737162
Kamada, N. et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J. Clin. Invest. 118, 2269–2280 (2008).
pubmed: 18497880
pmcid: 2391067
Bernardo, D. et al. Human intestinal pro-inflammatory CD11c
pubmed: 29743615
Ogino, T. et al. Increased Th17-inducing activity of CD14
pubmed: 23993972
Mazlam, M. Z. & Hodgson, H. J. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 33, 773–778 (1992).
pubmed: 1624158
pmcid: 1379334
Schwarzmaier, D., Foell, D., Weinhage, T., Varga, G. & Dabritz, J. Peripheral monocyte functions and activation in patients with quiescent Crohn’s disease. PLOS ONE 8, e62761 (2013).
pubmed: 23658649
pmcid: 3637246
Radwan, P., Radwan-Kwiatek, K., Tabarkiewicz, J., Radej, S. & Rolinski, J. Enhanced phenotypic and functional maturation of monocyte-derived dendritic cells from patients with active Crohn’s disease and ulcerative colitis. J. Physiol. Pharmacol. 61, 695–703 (2010).
pubmed: 21224500
Glasser, A. L. & Darfeuille-Michaud, A. Abnormalities in the handling of intracellular bacteria in Crohn’s disease: a link between infectious etiology and host genetic susceptibility. Arch. Immunol. Ther. Exp. (Warsz.) 56, 237–244 (2008).
Dige, A. et al. Reduced numbers of mucosal DR
pubmed: 26784676
Neurath, M. F. IL-23: a master regulator in Crohn disease. Nat. Med. 13, 26–28 (2007).
pubmed: 17206128
Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116, 1310–1316 (2006).
pubmed: 16670770
pmcid: 1451201
Duerr, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461–1463 (2006).
pubmed: 17068223
pmcid: 4410764
Vos, A. C. et al. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 140, 221–230 (2011).
pubmed: 20955706
Vos, A. C. et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm. Bowel Dis. 18, 401–408 (2012).
pubmed: 21936028
Papamichael, K. et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm. Bowel Dis. 21, 182–197 (2015).
pubmed: 25222660
Bantel, H. et al. Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol. 95, 3452–3457 (2000).
pubmed: 11151876
Mowat, C. et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 60, 571–607 (2011).
pubmed: 21464096
Oakley, R. H. & Cidlowski, J. A. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J. Allergy Clin. Immunol. 132, 1033–1044 (2013).
pubmed: 24084075
pmcid: 4084612
Ehrchen, J. et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 109, 1265–1274 (2007).
Giles, K. M. et al. Glucocorticoid augmentation of macrophage capacity for phagocytosis of apoptotic cells is associated with reduced p130Cas expression, loss of paxillin/pyk2 phosphorylation, and high levels of active Rac. J. Immunol. 167, 976–986 (2001).
pubmed: 11441106
Allgayer, H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment. Pharmacol. Ther. 18 (Suppl. 2), 10–14 (2003).
Atreya, I. et al. Designer thiopurine-analogues for optimised immunosuppression in inflammatory bowel diseases. J. Crohns Colitis 10, 1132–1143 (2016).
pubmed: 27112707
Feagan, B. G. et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N. Engl. J. Med. 342, 1627–1632 (2000).
pubmed: 10833208
Elion, G. B. The purine path to chemotherapy. Science 244, 41–47 (1989).
pubmed: 2649979
Marinkovic, G., Hamers, A. A., de Vries, C. J. & de Waard, V. 6-Mercaptopurine reduces macrophage activation and gut epithelium proliferation through inhibition of GTPase Rac1. Inflamm. Bowel Dis. 20, 1487–1495 (2014).
pubmed: 25029617
Municio, C. et al. Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase/p53 axis. Ann. Rheum. Dis. 75, 2157–2165 (2016).
pubmed: 26920997
Lucas, M., Zhang, X., Prasanna, V. & Mosser, D. M. ERK activation following macrophage FcγR ligation leads to chromatin modifications at the IL-10 locus. J. Immunol. 175, 469–477 (2005).
pubmed: 15972681
Pander, J. et al. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin. Cancer Res. 17, 5668–5673 (2011).
pubmed: 21788356
Boyer, J. F. et al. Anti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling. Arthritis Res. Ther. 18, 56 (2016).
pubmed: 26932562
pmcid: 4774095
Paramsothy, S., Rosenstein, A. K., Mehandru, S. & Colombel, J. F. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol. 11, 1558–1570 (2018).
pubmed: 29907872
pmcid: 6279599
De Vries, L. C. S., Wildenberg, M. E., De Jonge, W. J. & D’Haens, G. R. The future of janus kinase inhibitors in inflammatory bowel disease. J. Crohns Colitis 11, 885–893 (2017).
pubmed: 28158411
pmcid: 5881740
Machado, M. A. A. et al. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res. Ther. 20, 60 (2018).
pubmed: 29566769
pmcid: 5865387
Sandborn, W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723–1736 (2017).
pubmed: 28467869
Panes, J. et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut 66, 1049–1059 (2017).
pubmed: 28209624
pmcid: 5532457
Vermeire, S. et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389, 266–275 (2017).
pubmed: 27988142
Pattison, M. J., Mackenzie, K. F. & Arthur, J. S. Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J. Immunol. 189, 2784–2792 (2012).
pubmed: 22904308
pmcid: 3443740
Spadaccini, M., D’Alessio, S., Peyrin-Biroulet, L. & Danese, S. PDE4 inhibition and inflammatory bowel disease: a novel therapeutic avenue. Int. J. Mol. Sci. 18, E1276 (2017).
pubmed: 28617319
Mazur, M., Karczewski, J., Lodyga, M., Zaba, R. & Adamski, Z. Inhibitors of phosphodiesterase 4 (PDE 4): a new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis. J. Dermatolog. Treat. 26, 326–328 (2015).
pubmed: 25424050
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02289417 (2019).
Danese, S. et al. Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study [abstract OP006]. J. Crohns Colitis 12, S004–S005 (2018).
Barrera, P. et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. 43, 1951–1959 (2000).
pubmed: 11014344
pmcid: 11014344
Bu, L., Gao, M., Qu, S. & Liu, D. Intraperitoneal injection of clodronate liposomes eliminates visceral adipose macrophages and blocks high-fat diet-induced weight gain and development of insulin resistance. AAPS J. 15, 1001–1011 (2013).
pubmed: 23821353
pmcid: 3787235
Piaggio, F. et al. A novel liposomal clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects. J. Control. Release 223, 165–177 (2016).
pubmed: 26742942
Poh, A. R. & Ernst, M. Targeting macrophages in cancer: from bench to bedside. Front. Oncol. 8, 49 (2018).
pubmed: 29594035
pmcid: 5858529
Marra, M. et al. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol. Adv. 30, 302–309 (2012).
pubmed: 21741464
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399–416 (2017).
pubmed: 28117416
pmcid: 28117416
Binnemars-Postma, K., Storm, G. & Prakash, J. Nanomedicine strategies to target tumor-associated macrophages. Int. J. Mol. Sci. 18, E979 (2017).
pubmed: 28471401
Singh, Y. et al. Targeting tumor associated macrophages (TAMs) via nanocarriers. J. Control. Release 254, 92–106 (2017).
pubmed: 28377038
Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14–20 (2014).
pubmed: 25035950
pmcid: 25035950
Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958–969 (2008).
pubmed: 19029990
pmcid: 2724991
Shapouri-Moghaddam, A. et al. Macrophage plasticity, polarization, and function in health and disease. J. Cell. Physiol. 233, 6425–6440 (2018).
pubmed: 29319160
Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686 (2004).
pubmed: 15530839
Martinez, F. O., Sica, A., Mantovani, A. & Locati, M. Macrophage activation and polarization. Front. Biosci. 13, 453–461 (2008).
pubmed: 17981560
Arora, S., Dev, K., Agarwal, B., Das, P. & Syed, M. A. Macrophages: their role, activation and polarization in pulmonary diseases. Immunobiology 223, 383–396 (2018).
pubmed: 29146235
Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896 (2010).
pubmed: 20856220
pmcid: 20856220
Wynn, T. A. & Vannella, K. M. Macrophages in tissue repair, regeneration, and fibrosis. Immunity 44, 450–462 (2016).
pubmed: 26982353
pmcid: 4794754
Colin, S., Chinetti-Gbaguidi, G. & Staels, B. Macrophage phenotypes in atherosclerosis. Immunol. Rev. 262, 153–166 (2014).
pubmed: 25319333
Ambarus, C. A. et al. Soluble immune complexes shift the TLR-induced cytokine production of distinct polarized human macrophage subsets towards IL-10. PLOS ONE 7, e35994 (2012).
pubmed: 22563430
pmcid: 3338562
Yue, Y. et al. M2b macrophages reduce early reperfusion injury after myocardial ischemia in mice: a predominant role of inhibiting apoptosis via A20. Int. J. Cardiol. 245, 228–235 (2017).
pubmed: 28764858
Roszer, T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015, 816460 (2015).
pubmed: 26089604
pmcid: 4452191
Zizzo, G., Hilliard, B. A., Monestier, M. & Cohen, P. L. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J. Immunol. 189, 3508–3520 (2012).
pubmed: 3465703
pmcid: 3465703
Wang, Q. et al. Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Res. 20, 701–712 (2010).
pubmed: 20386569
Wu, H. et al. Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. J. Surg. Oncol. 106, 462–468 (2012).
pubmed: 22488237
Rivollier, A., He, J., Kole, A., Valatas, V. & Kelsall, B. L. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J. Exp. Med. 209, 139–155 (2012).
pubmed: 22231304
pmcid: 3260867